135 related articles for article (PubMed ID: 24092811)
1. Tetravalent antibody-scTRAIL fusion proteins with improved properties.
Seifert O; Plappert A; Fellermeier S; Siegemund M; Pfizenmaier K; Kontermann RE
Mol Cancer Ther; 2014 Jan; 13(1):101-11. PubMed ID: 24092811
[TBL] [Abstract][Full Text] [Related]
2. Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity.
Siegemund M; Pollak N; Seifert O; Wahl K; Hanak K; Vogel A; Nussler AK; Göttsch D; Münkel S; Bantel H; Kontermann RE; Pfizenmaier K
Cell Death Dis; 2012 Apr; 3(4):e295. PubMed ID: 22495350
[TBL] [Abstract][Full Text] [Related]
3. Superior Properties of Fc-comprising scTRAIL Fusion Proteins.
Hutt M; Marquardt L; Seifert O; Siegemund M; Müller I; Kulms D; Pfizenmaier K; Kontermann RE
Mol Cancer Ther; 2017 Dec; 16(12):2792-2802. PubMed ID: 28904131
[TBL] [Abstract][Full Text] [Related]
4. IgG-single-chain TRAIL fusion proteins for tumour therapy.
Siegemund M; Schneider F; Hutt M; Seifert O; Müller I; Kulms D; Pfizenmaier K; Kontermann RE
Sci Rep; 2018 May; 8(1):7808. PubMed ID: 29773864
[TBL] [Abstract][Full Text] [Related]
5. An optimized antibody-single-chain TRAIL fusion protein for cancer therapy.
Siegemund M; Seifert O; Zarani M; Džinić T; De Leo V; Göttsch D; Münkel S; Hutt M; Pfizenmaier K; Kontermann RE
MAbs; 2016 Jul; 8(5):879-91. PubMed ID: 27064440
[TBL] [Abstract][Full Text] [Related]
6. Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins.
Schneider B; Münkel S; Krippner-Heidenreich A; Grunwald I; Wels WS; Wajant H; Pfizenmaier K; Gerspach J
Cell Death Dis; 2010 Aug; 1(8):e68. PubMed ID: 21364672
[TBL] [Abstract][Full Text] [Related]
7. APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptors.
Gieffers C; Kluge M; Merz C; Sykora J; Thiemann M; Schaal R; Fischer C; Branschädel M; Abhari BA; Hohenberger P; Fulda S; Fricke H; Hill O
Mol Cancer Ther; 2013 Dec; 12(12):2735-47. PubMed ID: 24101228
[TBL] [Abstract][Full Text] [Related]
8. CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants.
Trebing J; El-Mesery M; Schäfer V; Weisenberger D; Siegmund D; Silence K; Wajant H
Cell Death Dis; 2014 Jan; 5(1):e1035. PubMed ID: 24481449
[TBL] [Abstract][Full Text] [Related]
9. The eIg technology to generate Ig-like bispecific antibodies.
Kühl L; Aschmoneit N; Kontermann RE; Seifert O
MAbs; 2022; 14(1):2063043. PubMed ID: 35427197
[TBL] [Abstract][Full Text] [Related]
10. Targeting scFv-Fc-scTRAIL fusion proteins to tumor cells.
Hutt M; Fellermeier-Kopf S; Seifert O; Schmitt LC; Pfizenmaier K; Kontermann RE
Oncotarget; 2018 Feb; 9(13):11322-11335. PubMed ID: 29541416
[TBL] [Abstract][Full Text] [Related]
11. The IgM CH2 domain as covalently linked homodimerization module for the generation of fusion proteins with dual specificity.
Seifert O; Plappert A; Heidel N; Fellermeier S; Messerschmidt SK; Richter F; Kontermann RE
Protein Eng Des Sel; 2012 Oct; 25(10):603-12. PubMed ID: 22988132
[TBL] [Abstract][Full Text] [Related]
12. CD40-directed scFv-TRAIL fusion proteins induce CD40-restricted tumor cell death and activate dendritic cells.
El-Mesery M; Trebing J; Schäfer V; Weisenberger D; Siegmund D; Wajant H
Cell Death Dis; 2013 Nov; 4(11):e916. PubMed ID: 24232092
[TBL] [Abstract][Full Text] [Related]
13. Targeted induction of apoptosis in glioblastoma multiforme cells by an MRP3-specific TRAIL fusion protein in vitro.
Wang LH; Ni CW; Lin YZ; Yin L; Jiang CB; Lv CT; Le Y; Lang Y; Zhao CY; Yang K; Jiao BH; Yin J
Tumour Biol; 2014 Feb; 35(2):1157-68. PubMed ID: 24272336
[TBL] [Abstract][Full Text] [Related]
14. A novel humanized anti-tumor necrosis factor-related apoptosis-inducing ligand-R2 monoclonal antibody induces apoptotic and autophagic cell death.
Chen L; Qiu Y; Hao Z; Cai J; Zhang S; Liu Y; Zheng D
IUBMB Life; 2017 Sep; 69(9):735-744. PubMed ID: 28748573
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.
Michaelson JS; Demarest SJ; Miller B; Amatucci A; Snyder WB; Wu X; Huang F; Phan S; Gao S; Doern A; Farrington GK; Lugovskoy A; Joseph I; Bailly V; Wang X; Garber E; Browning J; Glaser SM
MAbs; 2009; 1(2):128-41. PubMed ID: 20061822
[TBL] [Abstract][Full Text] [Related]
16. Pentamerisation of a scFv directed against TRAIL receptor 2 increases its antitumour efficacy.
Wang W; He W; Wang L; Zhang G; Gao B
Immunol Cell Biol; 2013 May; 91(5):360-7. PubMed ID: 23567896
[TBL] [Abstract][Full Text] [Related]
17. A Novel Fully Human Agonistic Single Chain Fragment Variable Antibody Targeting Death Receptor 5 with Potent Antitumor Activity In Vitro and In Vivo.
Lei G; Xu M; Xu Z; Gu L; Lu C; Bai Z; Wang Y; Zhang Y; Hu H; Jiang Y; Zhao W; Tan S
Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28953230
[TBL] [Abstract][Full Text] [Related]
18. A Fas Ligand (FasL)-Fused Humanized Antibody Against Tumor-Associated Glycoprotein 72 Selectively Exhibits the Cytotoxic Effect Against Oral Cancer Cells with a Low FasL/Fas Ratio.
Chien MH; Chang WM; Lee WJ; Chang YC; Lai TC; Chan DV; Sharma R; Lin YF; Hsiao M
Mol Cancer Ther; 2017 Jun; 16(6):1102-1113. PubMed ID: 28292939
[TBL] [Abstract][Full Text] [Related]
19. A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity.
Zhu D; Wang X; Shang Y; Li Y; Jiang W; Li L; Chen SZ
Anticancer Drugs; 2015 Jan; 26(1):64-73. PubMed ID: 25122444
[TBL] [Abstract][Full Text] [Related]
20. Ad-KDRscFv:sTRAIL displays a synergistic antitumor effect without obvious cytotoxicity to normal tissues.
Yang L; Guo J; Wang J; Wan S; Yang S; Wang R; Chen W; Peng G; Fang D
Int Immunopharmacol; 2012 May; 13(1):37-45. PubMed ID: 22406047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
